Search results “Pancreatic cancer action network aacr”
Pancreatic Cancer Action Network - Awareness Video
How pancreatic cancer has affected the Normandin family
Views: 490 Nicole Normandin
Be a Hero. Make Pancreatic Cancer Research a National Priority.
http://pancan.org/ Grantee: David Dawson, MD, PhD Institution: University of California, Los Angeles Research Project: Wnt Signaling in Pancreatic Cancer Progenitor Cells Award: 2008 Seena Magowitz -- Pancreatic Cancer Action Network -- AACR Career Development Award Award Period: July 1, 2008 -- June 30, 2010 Amount: $100,000
About Pancreatic Cancer
Learn basic information about the pancreas and pancreatic cancer from leading experts in the field. Dr. Margaret Tempero, Professor of Medicine at the University of California, San Francisco, and Dr. George Fisher, Associate Professor of Medicine at Stanford University, provide a general overview of the disease, types of pancreatic cancer, and treatment options.
Meet researcher Zeshaan Rasheed, MD, PhD of Johns Hopkins University
http://pancan.org/ Dr. Rasheed is the recipient of the 2010 Tempur-Pedic Retailers -- Pancreatic Cancer Action Network -- AACR Pathway to Leadership Grant. His pivotal studies aim to identify and analyze the cancer stem cells (CSC) population within pancreatic tumors. Specifically, Dr. Rasheed's goal is to better understand the origin of the CSC, and to determine whether regular non-CSC cancer cells have the ability to become CSCs in response to particular external stimuli. This project will lay the groundwork for future investigations on targeting these highly aggressive cells within a pancreatic tumor cell population.
Pancreatic Cancer: Challenges and Solutions
Presented at Cancer Research & Oncology 2017 Lynn Matrisian, PhD, MBA - Chief Science Officer, Pancreatic Cancer Action Network Lynn M. Matrisian, PhD, MBA, is Chief Science Officer at the Pancreatic Cancer Action Network, based in Manhattan Beach, CA and Washington DC. She focuses on understanding and impacting the scientific and medical activities within the pancreatic cancer field to advance the organizations goal to double survival from pancreatic cancer by the year 2020. She has oversight of the organization's research activities, including the Grants Program, Clinical Trial Finder, Patient Registry, Know Your Tumor and Early Detection Initiative, and sits on the Executive Committee of the personalized medicine initiative Precision Promise. Dr. Matrisian is formerly Professor and the founding Chair of the Department of Cancer Biology at Vanderbilt University. She received her PhD in molecular biology from the University of Arizona and MBA from Vanderbilt University. She is past President of the American Association of Cancer Research, a Fellow of the AACR Academy, and the recipient of the Paget-Ewing award from the Metastasis Research Society. She served as co-chair of the National Cancer Institute's Translational Research Working Group and Special Assistant to the Director of the NCI. Research in her laboratory revolved around the molecular mechanisms underlying tumor progression and metastasis, with emphasis on the biology of matrix-degrading proteinases. Pancreatic Cancer: Challenges and Solutions Pancreatic cancer is one of the “deadly” cancers, defined as those with a 5-year relative survival rate of less than 50%. Although ranking 12th in terms of incidence, it is on track to become the second leading cause of cancer deaths by 2020. The Pancreatic Cancer Action Network (PanCAN) set a goal of doubling survival by 2020, identified 5 specific challenges that need to be addressed, and initiated approaches to contribute to their solution. There are not enough researchers or research, the clinical trial enrollment rate is too low, clinical trials need to be streamlined and focused, there is insufficient public awareness, and most patients are seen in the community setting where there is little experience with the disease. Through advocating for government resources, the NCI allocation to pancreatic cancer has increased 5-fold since 1999, with several new research initiatives that resulted from the passage of the Recalcitrant Cancer Research Act in 2013. Patient Central associates served more than 33,000 patients and families last year, providing disease and treatment information, support resources, and clinical trial searches. The Patient Registry collects information from individual patients, learns best practices, and disseminates information on topics such as the use of pancreatic enzyme replace therapy to the scientific community. The Know Your Tumor ® initiative has enrolled more than 1300 patients from across the US, and delivered almost 700 reports thus far detailing the results from genomic and proteomic analysis of tumor tissue with treatment options based on the molecular profiling and consideration of treatment history. These results indicate that 25% of pancreatic cancer patients have “actionable alterations” that indicate a targeted therapy, and that the median progression-free survival of patients that utilize a report-directed targeted therapy increased by 46% over those with no highly actionable alteration. The clinical trial landscape in pancreatic cancer has changed over the past 5 years, with a doubling of those trials that test a targeted therapy and an increase in trials for recurrent disease. The accrual of pancreatic adenocarcinoma patients to clinical trials increased from 3.8% in 2011 to 4.2% in 2014; this is at least in part attributed to increased awareness of clinical trials through PanCAN’s Clinical Trial Finder (12% of those who access this service enroll in a clinical trial) and Know Your Tumor ® initiatives (21% of participants enroll in a clinical trial). PanCAN is initiating Precision PromiseSM , a clinical trial and research platform with the mission of continuously and rapidly evaluating novel treatment options for pancreatic cancer. Public awareness of the disease is raised... Earn PACE/CME Credits: 1. Make sure you’re a registered member of LabRoots : https://www.labroots.com/virtual-event/cancer-research-oncology-2017 2. Watch the webinar on YouTube above or on the LabRoots Website : https://www.labroots.com/virtual-event/cancer-research-oncology-2017 3. Click Here to get your PACE October 12, 2019 – http://www.labroots.com/credit/pace-credits/2532/third-party LabRoots on Social: Facebook: https://www.facebook.com/LabRootsInc Twitter: https://twitter.com/LabRoots LinkedIn: https://www.linkedin.com/company/labroots Instagram: https://www.instagram.com/labrootsinc Pinterest: https://www.pinterest.com/labroots/ SnapChat: labroots_inc
Views: 71 LabRoots
YOU Can Raise the Cure The Urgent Need To Support Pancreatic Cancer Research
Pancreatic cancer is the fourth leading cause of cancer deaths in the US, but receives the least amount of federal research dollars among the leading cancer killers. Research is the key to unlocking the mystery of this devastating disease. YOU can help raise the cure. Watch this in-depth video about the progress being made in pancreatic cancer research and what the future holds.
AACR: Drug Combo Shows Promise in Advanced Pancreatic Cancer
http://www.medpagetoday.com Daniel D. Von Hoff, M.D., of the Scottsdale Clinical Research Institute in Scottsdale, Ariz. SAN DIEGO, April 17 -- More than 70% of patients with pancreatic cancer derived a clinical benefit when treated in a small, phase I trial with the combination of nanoparticle albumin bound paclitaxel (Abraxane) and gemcitabine (Gemzar), investigators reported here. Medpage Today: http://medpagetoday.com Online CME - Continuing medical education: http://www.medpagetoday.com/cme/ Latest medical news: http://www.medpagetoday.com/latest/ The MedPage Today app: iOS: https://goo.gl/JKrkHq Android: https://play.google.com/store/apps/details?id=com.medpagetoday.medpage MedPage Today Youtube Channel: https://www.youtube.com/user/MedPageToday Medpage Today on Facebook: https://www.facebook.com/MedPageToday
Views: 1806 MedPage Today
Diane Simeone, MD:  Pancreatic Cancer Overview and Treatment Update from AACR 2012
Dr. Simeone gives an overview of pancreatic cancer including treatment research in the area of stem cells, presented at the AACR 2012 Annual Meeting in Chicago. Diane Simeone, MD is the Lazar J. Greenfield Professor of Surgery and Professor of Molecular & Integrative Physiology -- Chief, Division of Hepatopancreatobiliary and Advanced Gastrointestinal Surgery at the University of Michigan.
Margaret Tempero, MD:  A Pancreatic Cancer Expert and Longtime Supporter
Margaret Tempero, MD, is the Director of the Pancreas Center at the University of California, San Francisco, Professor of Medicine in the Division of Hematology and Oncology at the university, and a long-term member of the Pancreatic Cancer Action Network's Scientific Advisory Board. In this video, Dr. Tempero, a medical oncologist widely respected for her work in gastrointestinal cancers, explains how she initially came involved with the organization and why she continues to support its mission.
Pancreatic Cancer: More Than One Flavor?
In this videoblog, Dr. John Marshall talks about how our growing ability to prospectively define tumors according to their genetics is likely to be the key to applying highly effective anticancer treatments.
Views: 388 medvidblog
Daniel Laheru, M.D. - Pancreatic cancer clinical trial funded by Stand Up To Cancer
Daniel Laheru, M.D., medical oncologist at the Johns Hopkins Kimmel Cancer Center, discusses a pancreatic cancer clinical trial funded by Stand Up To Cancer.
Views: 1735 Johns Hopkins Kimmel
Heinz-Josef Lenz, MD:  Pancreas Cancer Data at ASCO 2013
Dr. Heinz-Josef Lenz sits down with Selma Schimmel in The Group Room to discuss pancreas cancer data at ASCO 2013. This interview was filmed at the American Society of Clinical Oncology Annual Meeting in Chicago 2013. Heinz-Josef Lenz, M.D., FACP, is the Associate Director for Clinical Research and Co-Leader of the Gastrointestinal Cancers Program at the USC Norris Comprehensive Cancer Center. Dr. Lenz is Professor of Medicine and Preventive Medicine, Section Head of GI Oncology in the Division of Medical Oncology and Co-Director of the Colorectal Center at the Keck School of Medicine of the University of Southern California.
SU2C: Katie Couric on Pancreatic Cancer
Katie Couric interviews Howard Young, a pancreatic cancer survivor who beat the odds and also discusses the latest advances in pancreatic cancer research with the Stand Up to Cancer Pancreatic Cancer Dream Team. To learn more about how SU2C is fighting pancreatic cancer, visit: http://su2c.org Stand up and donate: http://www.su2c.org/donate Stand Up To Cancer’s mission is to raise funds to accelerate the pace of groundbreaking translational research that can get new therapies to patients quickly and save lives now. Find out more about Stand Up To Cancer: http://www.standup2cancer.org Subscribe now to be notified of future live events and new uploads: https://www.youtube.com/su2c?sub_conf… Shop for Stand Up To Cancer merchandise: http://www.shopsu2c.org More Stand Up To Cancer channels: https://www.facebook.com/SU2C https://twitter.com/SU2C https://instagram.com/SU2C
Views: 1573 Stand Up To Cancer
L.A. Cancer Challenge Pancreatic Team Tribute Pt. 1
L.A. Cancer Challenge Team Tribute Pt. 1 is a tribute to all of those beautiful people who have been touched by pancreatic cancer. We miss them and ask you to join us in the fight against pancreatic cancer to stop this aweful disease! www.lacancerchallenge.com
Views: 261 Phillipnsoul
Dr Marina Pajic - Pancreatic Cancer Genome Sequencing
Garvan's Dr Marina Pajic (http://www.garvan.org.au/research/cancer/pancreatic-cancer-research/personalised-cancer-therapeutics/marpaj) presenting "Cancer genome sequencing: Developing personalised medicine strategies for pancreatic cancer"
Stem Cells in Pancreatic Cancer
Learn about pancreatic cancer from Diane Simeone, M.D., Surgical Director of the Multidisciplinary Pancreatic Cancer Clinic.
Views: 3065 Michigan Medicine
Surgery for Unresectable Pancreatic Cancer
John Chabot, MD of the Pancreas Center and surgeon at NewYork-Presbyterian Hospital/Columbia University Medical Center, discusses when surgery is appropriate for patients with pancreatic cancer as well as the advances made in pancreatic surgical options.
U-M researchers ID gene involved in pancreatic cancer
Pancreatic cancer is the 11th most common cause of cancer in the United States, but it is the 4th leading cause of cancer death. Each year, about 40-thousand Americans are diagnosed with the disease; within 5 years, almost all will die from it. University of Michigan Comprehensive Cancer Center researchers have uncovered an important piece of the puzzle.
Views: 2252 Michigan Medicine
Treating Pancreatic Cancer
Cancer of the pancreas is one of the most deadly forms of the disease. However, Siteman Cancer Center surgeon David Linehan, MD, says while it is difficult to treat, there are options out there, particularly in clinical trials.
New Innovations in Pancreatic Cancer Treatment
Pancreatic cancer patients at the Massachusetts General Hospital Cancer Center benefit from the innovative work of The Andrew L. Warshaw Institute for Pancreatic Cancer Research which includes a community of scientists, oncologists, surgeons, radiation oncologists and interventional endoscopists whose mission is to extend and improve the lives of patients with pancreatic cancer. More information visit: http://www.massgeneral.org/warshawinstitute/
Views: 1626 MassGeneralHospital
Government Funding for Cancer Research
Geoff Wahl Immediate Past President American Association for Cancer Research Professor, Salk Institute Question candidates about how they will ensure adequate funding for second most common cause death in US.
Views: 1413 pauldriscoll33
TGen & Pancreatic Cancer Research
Pancreatic Cancer is a vicious killer, the fourth leading cause of cancer death in the U.S., claiming a higher percentage of lives than any other form of cancer. Dr. Daniel Von Hoff leads the Clinical Translational Research Division at TGen which focuses on genetic and biochemical approaches to identify diagnostics and molecular targets for the development of new therapies for pancreatic cancer. Dr. Von Hoff and his team were instrumental in the development of an anti-cancer agent (gemcitabine) that significantly improves survival rates of patients with pancreatic cancer. TGen's efforts in pancreatic cancer research are aided by the fact that Dr. Von Hoff has coordinated the formation of a world-wide team of experts solely focused on pancreatic research, named the Pancreatic Cancer Research Team (PCRT). Scientists within the PCRT share knowledge and resources to make rapid advances in pancreatic research. PCRT specializes in using this knowledge to initiate clinical trials to allow patients immediate access to newly developed therapies.
Views: 1233 tgenvideo
Interview with Julie M. Fleshman, J.D., M.B.A.
Julie M. Fleshman, J.D., M.B.A., president and chief executive officer of the Pancreatic Cancer Action Network, and recipient of AACRs Distinguished Public Service Award, talks about her commitment to changing the course of pancreatic cancer.
Personalized Medicine in Bladder Cancer: A Summary of the Cancer Genome Atlas Findings
This presentation provides information about personalized medicine and what you should know about the Cancer Genome Atlas research findings in bladder cancer and future treatments for this disease. Features Speakers: Dr. Seth P. Lerner Chair of Urological Oncology Scott Department of Urology Baylor College of Medicine Dr. Jonathan E. Rosenberg Associate Attending Physician Genitourinary Oncology Service Memorial Sloan-Kettering Cancer Center Click here for more information: http://www.bcan.org/
Combination Therapy Increases Survival in Metastatic Lung Cancer Patients
Dr. Leena Gandhi, director of the thoracic medical oncology program at Perlmutter Cancer Center, discusses the results of a phase III clinical trial and its impact going forward in the treatment of non-squamous non-small cell lung cancer. Learn more about this study: https://nyulangone.org/press-releases/combination-of-pembrolizumab-and-chemotherapy-doubles-survival-in-patients-with-metastatic-lung-cancer Learn more about Perlmutter Cancer Center: https://nyulangone.org/locations/perlmutter-cancer-center Learn more about Dr. Leena Gandhi: https://nyulangone.org/doctors/1841275906/leena-gandhi Learn more about Lung Cancer: https://nyulangone.org/conditions/lung-cancer
Views: 524 NYU Langone Health
Cancer cell biology: mutated KRAS & reciprocal signalling
Across a wide variety of cancer types, a protein called KRAS can get hyperactivated and transmit an overload of unwanted growth signals to the cells, causing them to divide and form a tumour. A tumour doesn't just contain cancer cells, though. It also has some non-cancer cells in there, such as immune cells and fibroblasts (cells that make the dense support structure that keeps cells stuck together). New research by Chris Tape, Claus Jørgensen and colleagues at The Institute of Cancer Research in London, MIT, the Cancer Research UK Manchester Institute and The University of Manchester, has shed some new light on how mutated KRAS causes cancer cells to grow by promoting three distinct ways of cellular signalling: 1) Through a direct signalling pathway within the cancer cell, with KRAS signalling through the classic RAS-RAF-MEK-ERK signal transduction cascade, this is called cell-autonomous signalling. 2) By inducing the cancer cell to release a protein called SHH, which is able to start specific signalling pathways inside the fibroblast cells. This is called non-cell-autonomous signalling. 3) When these non-cell-autonomous signalling pathways in the fibroblast cells are induced, the fibroblasts are able to release growth factors that go back to the cancer cell, where they initiate more growth signalling pathways through a PI3K-AKT signal transduction cascade. Uncovering these new ways in which mutated KRAS is able to promote cancer cell growth by hijacking fibroblast cell signalling could lead to new possibilities for therapeutic intervention. To find out more about this fascinating research, you can read Chris' blogpost here: http://christape.com/, and you can find Claus' lab page here: http://www.cruk.manchester.ac.uk/Research/CRUK-MI-Groups/Systems-Oncology/Home References: - C.J. Tape, S. Ling, M. Dimitriadi, K.M. McMahon, J.D. Worboys, H.S. Leong, I.C. Norrie, C.J. Miller, G. Poulogiannis, D.A. Lauffenburger, C. Jørgensen, ‘Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation’, Cell (2016) 165(4) - Tape, C.J., (2016) Systems Biology Analysis of Heterocellular Signaling, Trends in Biotechnology (2016) 34(8) - Kolch, W., Halasz, M., Granovskaya, M., and Kholodenko, B.N. (2015). The dynamic control of signal transduction networks in cancer cells. Nat Rev Cancer 15, 515-527. - Quail, D.F., and Joyce, J.A. (2013). Microenvironmental regulation of tumor progression and metastasis. Nature medicine 19, 1423- 1437. - Friedl, P., and Alexander, S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 147, 992-1009.
Clinical Trial for Pancreatic Cancer - Dr. Steven M. Lipkin
Steven M. Lipkin, M.D., Ph.D., a Medical Geneticist at NewYork-Presbyterian Hospital/Weill Cornell Medical Center in New York City, discusses research projects he is conducting - specifically, a clinical trial to treat a type of pancreatic cancer. You can learn more about Dr. Lipkin at: http://www.weillcornell.org/physician/smlipkin/index.html
Mayo Clinic Researchers Formulate Treatment Combination Lethal To Pancreatic Cancer Cells
A combination of two targeted therapies packs a powerful punch to kill pancreatic cancer cells in the laboratory, Mayo Clinic cancer researchers report. With further testing of these drugs that are from classes of pharmaceuticals already used in patients, the Mayo research may lead to new treatment opportunities for patients with pancreatic cancer, which is extremely difficult to treat. In a study being presented at the annual meeting of the American Association for Cancer Research, Mayo Clinic Cancer Center investigators found that rapamycin and panobinostat (also known as LBH589) act synergistically when used in combination, destroying up to 65 percent of cultured pancreatic tumor cells. The finding is particularly significant, says the studys first author, Mamta Gupta, Ph.D., because the three cell lines studied were all resistant to the effects of chemotherapy — as are many pancreatic tumors — and because the drugs studied are already available for treatment of patients. Panobinostat is approved as therapy for cutaneous T cell lymphoma (CTCL), and rapamycin is best known as an immunosuppressant to help prevent rejection of transplanted organs.
Views: 1442 Mayo Clinic
Hirshberg Pancreatic Cancer Foundation part 2
Thanks so much for watching this video. The Hirshberg Foundation for Pancreatic Cancer Research at UCLA Medical center is celebrating it's 10th year of work against this terrible disease. This video shares some of the heart breaking stories of those families who have been touched by pancreatic cancer. Please visit our website at www.pancreatic.org and donate to our important cancer research work.
Views: 854 Phillipnsoul
A Merry Life Memorial Tribute for Another Life Taken by Pancreatic Cancer
My wife Merry recently died from pancreatic cancer at age 54. We made this tribute video from photos of her life.
Views: 813 John Ferns
Advancing Pancreatic Cancer Research at TGen
Headed by Dr. Daniel Von Hoff, TGen's Pancreatic Cancer Research Laboratory focuses on genetic and biochemical approaches to identify diagnostics and molecular targets for the development of new therapies for pancreatic cancer. Dr. Von Hoff and his team were instrumental in the development of one anti-cancer agent (gemcitabine) that significantly improves survival rates of patients with pancreatic cancer.
Views: 2026 tgenvideo
Chapter 2: About Pancreatic Cancer
Understanding Pancreatic Cancer
Views: 355 mediaoneaustralia
Stand Up to Cancer
Pancreatic cancer clinical trials are underway at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. The center is a primary clinical research site for the Stand Up to Cancer (SU2C) Dream Team pancreatic cancer research project. Daniel Von Hoff, MD, chief scientific officer at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and physician-in-chief at the Translational Genomics Research Institute (TGen), is co-leader of the Stand Up to Cancer pancreatic cancer Dream Team. Ramesh Ramanathan, MD is the medical director at Virginia G. Piper Cancer Center Clinical Trials. "Cutting Off the Fuel Supply, A New Approach to the Treatment of Pancreatic Cancer" clinical trials include: • Using a drug to break through the tough coating surrounding the cancer so a second drug can kill the cancer cells. This combination is showing positive preliminary results in actually shrinking tumors. • Another effort is examining a tumor's molecular profile using state-of-the art molecular profiling techniques to personalize treatment for individual patients. Cancer patients travel from across Arizona, the United States and beyond for treatment at the Virginia G. Piper Cancer Center at Scottsdale Healthcare. The center opened in 2001 as the first major cancer center in greater Phoenix to offer comprehensive cancer research, diagnosis, treatment, prevention and support services in a single location. To learn about eligibility to participate in clinical trials at the Virginia G. Piper Cancer Center at Scottsdale Healthcare, contact the cancer care coordinator at 480-323-1339, toll free at 1-877-273-3713 or clinicaltrials@shc.org. For more information about current studies, visit http://www.shc.org/clinicaltrials. Follow us on Twitter at http://www.twitter.com/SHCpublicinfo and on Facebook at http://www.facebook.com/scottsdalehealthcare.
LA Cancer Challenge on Time Warner
Lisa Manheim, Director of the Hirshberg Foundation for Pancreatic Cancer Research is interviewed for the Time Warner show.
Views: 504 Phillipnsoul
My Cure Cancer Moonshot: Technologies in this room will change care
Joe Biden talking to a group of transformative Healthcare entrepreneurs about his Cancer Moonshot and encouraging them to keep pushing as that is what change takes.
Physicians React to Phase 2 Update on GenSpera’s Mipsagargin in Hepatocellular Carcinoma at ASCO GI
Attendees react to the results of a Phase II study of GenSpera’s mipsagargin (G-202), an investigational agent for the treatment of hepatocellular carcinoma (HCC), presented at ASCO GI 2015 on January 16, 2015, and discuss the global unmet needs for the liver cancer community. - Austin Duffy, M.D., from National Cancer Institute - Renuka Iyer, M.D., from Roswell Park Cancer Institute - Muhammad Shaalan Beg, M.D., from UT Southwestern Medical Center Learn more at www.genspera.com.
Views: 233 GenSpera, Inc.
National Cancer Intelligence Network - Presentation at the InstantAtlas User Conference, London 2012
The National Cancer Intelligence Network (NCIN) is a UK-wide initiative, working to drive improvements in standards of care and clinical outcomes by improving data and information collected about cancer patients, producing analyses and enabling and promoting research. Read the full story here - http://www.instantatlas.com/NCIN_story.xhtml
Views: 350 InstantAtlas
Seena Magowitz Foundation Banquet 2009
2009 Seena Magowitz Foundation Banquet and Casino Night, December 4, 5 2009 held at the Westin Kierland Resort in Scottsdale, Arizona. Video slide presentation compliments of Donovan's Steakhouse in Phoenix, Arizona as a public service. http://www.seenamagowitzfoundation.org/ http://www.donovanssteakhouse.com/phoenix-steakhouse.html
Steve Medley Photo Tribute
Photo montage of Steve Medley. He was taken from us by pancreatic cancer. Feb 5 2008 We miss you Steve.
Views: 676 John Medley
Obesity and Breast Cancer
It wasn't until seven years ago that even the medical community fully understood the link between body fat and cancer risk. "We used to think that adipose tissue, or body fat, was just there doing nothing," said Dr. Elisa Bandera, a cancer epidemiologist at the Cancer Institute of New Jersey. "Now we know adipose is very active and transforms androgen into estrogen," she added. "Most of the estrogen that postmenopausal women have in their bodies is from the adipose tissue. This has become a very serious issue in cancer prevention." The shift in understanding was confirmed in 2003 when The New England Journal of Medicine published a paper by the American Cancer Society linking obesity to all kinds of cancerous tumors. Losing excess weight helps prevent breast cancer in women and decreases the risk of recurrence in breast cancer survivors.
Views: 544 Mayer Eisenstein
Insidermedicine in 60 - May 29, 2008
From Washington - Early childhood exposure to lead may cause permanent brain damage, and may even lead to criminal behaviour. By anaylsing the blood lead concentrations of pregnant women, as well as those of 250 children, researchers found that arrest rates increased as lead concentrations went up. An increase of 5 micrograms per deciliter increased the rate of arrest for violent offenses by over 25%. From the Netherlands - The corticosteroid drug prednisolone is just as effective at treating gout as the conventional treatment naproxen. In a randomized clinical trial of 120 patients with gout, those that received prednisolone reported a nearly equal reduction in pain as those that received naproxen. Adverse effects were also found to be similar in the two groups, and were resolved within 3 weeks. And finally from Paris - According to research published in the Lancet, patients with pancreatic cancer that are given axitinib in addition to standard treatment have an increased likelihood of survival than those given standard treatment alone. In a study of 103 patients with pancreatic cancer, those that received axitinib had a 29% decreased risk of death. Pancreatic cancer causes 227,000 deaths worldwide each year. For Insidermedicine in 60, I'm Dr. Susan Sharma.
Views: 671 insidermedicine
TRACO 2017 - Clinical trials and Precision Medicine
TRACO 2017 - Clinical trials and Precision Medicine Air date: Monday, September 11, 2017, 4:00:00 PM Category: TRACO Runtime: 02:00:08 Description: Translational Research in Clinical Oncology (TRACO) Recent advances in understanding cancer biology are beginning to be translated into improvements in diagnosis and treatment of cancer. In the post-genome era, we increasingly rely on strong collaboration between basic and clinical scientists to develop novel approaches for treatment of human disease. The NCI Center for Cancer Research (CCR) is one of the largest cancer research organizations in the world, with more than 200 principal investigators, and has played a major role in developing and implementing many new technologies, such as nanotechnology, next generation sequencing, genomics and proteomics. For more information go to http://ccr.cancer.gov/trainee-resources-courses-workshops-traco Author: Jill Smith, MD, Georgetown University and Curtis C. Harris, M.D., NCI, NIH Permanent link: https://videocast.nih.gov/launch.asp?23453
Views: 815 nihvcast
Dr. Baselga Discusses the BOLERO Breast Cancer Trials
José Baselga, MD, PhD, a professor in the Department of Medicine at Harvard Medical School and chief of Hematology/Oncology at Massachusetts General Hospital, describes the 3 phase III BOLERO trials investigating everolimus (Afinitor), a mammalian target of rapamycin inhibitor, in various stages of breast cancer. 1. BOLERO-1 is still recruiting patients; it seeks to add first-line everolimus to trastuzumab (Herceptin) and paclitaxel in women with HER2-positive locally advanced or metastatic breast cancer. 2. BOLERO-2 demonstrated the efficacy of adding everolimus to exemestane in women with aromatase inhibitor resistant, hormone receptor-positive, metastatic breast cancer. It successfully extended the time to disease progression by 4.2 months (HR, 0.44). 3. BOLERO-3, which is still recruiting patients, will combine everolimus with trastuzumab and vinorelbine for post-menopausal HER2-positive breast cancer that is resistant to trastuzumab. If the results from the BOLERO-1 and 3 trials are as positive as BOLERO-2 they will demonstrate the efficacy of everolimus in HER2-positive breast cancer, in both the first-line and refractory setting. BOLERO-2 was a second-line trial; Baselga feels a follow up study should include the first-line and adjuvant setting. The findings of the BOLERO-2 trial go far beyond the patient population in the study. This research opens up the entire field of mTOR/PI3K-targeted therapies in multiple tumor types.
Views: 793 OncLiveTV
The Lancet Oncology Commission: Future Cancer Research Priorities in the USA — Part 1
The Lancet Oncology Commission: Future Cancer Research Priorities in the USA — Part 2 Top scientists discuss how they recommend expanding and implementing the Blue Ribbon Panel’s road map for cancer research. They’ll discuss a report that will be published by the journal The Lancet Oncology and is co-edited by Elizabeth Jaffee, M.D., deputy director of the Johns Hopkins Kimmel Cancer Center, and Chi Van Dang, M.D., Ph.D., scientific director at Ludwig Cancer Research and professor at The Wistar Institute. Visit Johns Hopkins inHealth at: https://www.hopkinsmedicine.org/inhealth
A Little Bit of Evil Goes a Long Way
A little bit of evil can devastate the largely benign goodness that surrounds us. Your whole day could be ruined if you got lynched even once, though most other people were pretty decent to you. Evil on a few big things involving lots of people and their prejudices can trump huge amounts of goodness among individuals and small groups. We need goodness to operate on multiple levels and scales. Trying to demonstrate that large numbers of benign good things done on a daily basis by ordinary people prove that people will act in a particular way when in large groups, lacking empathy with the minority, does not work. Tell me how large numbers of people are going to make decisions forgoing their immediate satisfaction (financial or otherwise) in favor of long term good decisions affecting themselves and their neighbors. I still haven't heard it. And I suspect I won't. Remember that getting most of it right may not be enough, even though perfection can't be achieved. A little bit of evil, especially some carefully selected evil, goes a long way. Yep, he was pretty darned healthy. Except for his pancreas.
Views: 104 notstefbot
Mehran F Moghaddam | USA | Mass Spectrometry 2015| Conference Series LLC
International Summit on Current Trends in Mass Spectrometry July 13-15, 2015 New Orleans, USA Title: Utility of Mass Spectrometry in Drug metabolism and pharmacokinetics (DMPK): Discovery of Small Molecule Drugs Click here for Abstract and Biography: http://www.massspectra.com/speaker/2015/mehran-f-moghaddam-celgene-corporation-usa OMICS International: http://conferenceseries.com/ OMICS open access Journals: http://omicsonline.org Global Medical Conferences: http://conferenceseries.com Global Pharmaceutical Conferences: http://pharmaceuticalconferences.com Global Cancer Conferences: http://cancersummit.org Global Diabetes Conferences: http://diabetesexpo.com Global Dental Conferences: http://dentalcongress.com Global Nursing Conferences: http://nursingconference.com
What Impedes Cancer Research?
Dr. Harold Varmus, director of the National Cancer Institute, addressed reporters at the National Press Club as part of their news makers series.
Views: 6466 NCINews